Catalyst Funds Management Pty LTD C4 Therapeutics, Inc. Transaction History
Catalyst Funds Management Pty LTD
- $662 Billion
- Q3 2025
A detailed history of Catalyst Funds Management Pty LTD transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 42,500 shares of CCCC stock, worth $104,975. This represents 0.01% of its overall portfolio holdings.
Number of Shares
42,500Holding current value
$104,975% of portfolio
0.01%Shares
2 transactions
Others Institutions Holding CCCC
# of Institutions
109Shares Held
55.4MCall Options Held
329KPut Options Held
186K-
Lynx1 Capital Management LP San Juan, PR7.1MShares$17.5 Million3.06% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.05MShares$17.4 Million0.95% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.24MShares$12.9 Million0.4% of portfolio
-
Morgan Stanley New York, NY4.97MShares$12.3 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.85MShares$12 Million0.06% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $121M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...